Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 704 people in total, split across four groups depending on whether they received plasma exchange (a procedure that filters the blood) and whether they received a standard or reduced dose of steroid-type medicines called glucocorticoids. The trial was measuring whether plasma exchange made a difference to serious outcomes — specifically, how many participants either died from any cause or developed end-stage kidney disease (meaning their kidneys had failed badly enough to need at least 12 weeks of ongoing kidney replacement treatment such as dialysis). The reported data shows that, for the main outcome, 100 out of the participants in the plasma exchange groups reached the combined endpoint of death or end-stage kidney disease, compared with 109 out of the participants in the no plasma exchange groups. For the secondary outcomes, the number of participants who achieved sustained remission (disease under control from before six months and remaining stable to at least 12 months) was reported as 200 in the plasma exchange groups and 197 in the no plasma exchange groups. Serious infection events — infections serious enough to need intravenous antibiotics or a hospital stay — were recorded as 145 events in the plasma exchange groups and 132 in the no plasma exchange groups. Quality-of-life scores were also measured using standard questionnaires; on the physical health scale (scored 0–100, where higher means better), the plasma exchange groups averaged 39.04 and the no plasma exchange groups averaged 37.96. Mental health scores were 51.94 versus 51.40, and a separate overall health score (where 1 represents perfect health) was 0.79 versus 0.77, respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 32053298) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Vasculitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed (either recently or in the past) with a condition called granulomatosis with polyangiitis or microscopic polyangiitis (two types of blood vessel inflammation)
- You have had a positive blood test for specific antibodies linked to these conditions (called PR3-ANCA or MPO-ANCA)
- Your condition is severe, meaning it has affected your kidneys — shown by a kidney biopsy or abnormal urine results, AND your kidneys are not filtering blood well enough (confirm with trial site for exact levels)
- OR your condition has caused bleeding in the lungs, shown by a chest X-ray or CT scan, with no other explanation for the findings, AND supported by evidence such as coughing up blood, low red blood cell levels, or findings during a lung examination procedure
- You (or someone who makes decisions on your behalf) have agreed to take part by signing a consent form
Who may not be able to join:
- You have a different type of blood vessel inflammation that is not granulomatosis with polyangiitis or microscopic polyangiitis
- You have tested positive for a specific antibody called anti-GBM, or your kidney biopsy showed a particular pattern of immune deposits (confirm with trial site)
- You have been on dialysis for more than 21 days just before entering the trial, or you have previously had a kidney transplant
- You are under 15 years of age
- You are pregnant at the time of joining the study
- You have recently received certain treatments — including more than one IV dose of cyclophosphamide, more than 14 days of cyclophosphamide tablets, more than 14 days of high-dose steroid tablets, or more than one dose of rituximab — within the 28 days before joining the trial
- You have another health condition that, in the doctor's opinion, would make it unsafe to use the treatments involved in this trial (confirm with trial site)
- You have had a plasma exchange procedure (a blood-filtering treatment) within the 3 months before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Jayne, MD, Cambridge University Hospitals NHS Foundation Trust
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
18 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Composite of i) All-cause Mortality or ii) End-stage Renal Disease
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.